Nile Pharmaceuticals results, Q4 2023
Net profit, assets, equity and cash flow for Q4 2023, against the same period a year earlier, from the published financial statements. fiscal year starts in July.
Net profit119 millionEGP · +32.9% vs the same period a year earlier
Total assets1.04 billionEGP · +35.0% vs the same period a year earlier
Shareholders' equity478 millionEGP · +11.1% vs the same period a year earlier
Operating cash flow-41.73 millionEGP · −949.9% vs the same period a year earlier
In short
- Nile Pharmaceuticals's net profit for Q4 2023 was about 119 million EGP, up +32.9% from 89.67 million EGP in Q4 2022.
- Total assets at the end of Q4 2023 were about 1.04 billion EGP, and shareholders' equity about 478 million EGP.
- Operating cash flow for Q4 2023 was negative at 41.73 million EGP.
Key lines against the same period a year earlier
This periodQ4 2022Change
Net profit119 million89.67 million+32.9%
Gross profit595 million535 million+11.1%
Total assets1.04 billion769 million+35.0%
Total liabilities560 million339 million+65.4%
Shareholders' equity478 million431 million+11.1%
Total liabilities and equity1.04 billion769 million+35.0%
Operating cash flow-41.73 million4.91 million−949.9%
Investing cash flow-27.52 million-48 million+42.7%
Financing cash flow273 million-12.62 million+2260.1%
Net change in cash-11.38 million-55.71 million+79.6%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Nile Pharmaceuticals's Q1 2027 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy